Dientamoebiasis medical therapy: Difference between revisions
No edit summary |
|||
| Line 37: | Line 37: | ||
(2). Metronidazole is a nitroimidazole drug. The nitroimidazole drugs secnidazole and ornidazole have been used to treat D. fragilis infection but are unavailable in the United States. | (2). Metronidazole is a nitroimidazole drug. The nitroimidazole drugs secnidazole and ornidazole have been used to treat D. fragilis infection but are unavailable in the United States. | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 15:40, 29 November 2012
|
Dientamoebiasis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dientamoebiasis medical therapy On the Web |
|
American Roentgen Ray Society Images of Dientamoebiasis medical therapy |
|
Risk calculators and risk factors for Dientamoebiasis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: : Kalsang Dolma, M.B.B.S.[2]
Overview
Medical Therapy
- Shown below is a table summarizing the empiric treatment for dientamoebiasis.[1]
| Pathogens | Preferred Treatment | Duration of Treatment |
| Dientamoeba fragilis | Iodoquinol 650 mg orally 3 times daily
OR Paromomycin 25–35 mg per kg per day orally, in 3 divided doses OR Metronidazole (2) 500–750 mg orally 3 times daily |
Iodoquinol for 20 days
OR Paromomycin for 7 days OR Metronidazole for 10 days |
(1). Not FDA-approved for this indication.
(2). Metronidazole is a nitroimidazole drug. The nitroimidazole drugs secnidazole and ornidazole have been used to treat D. fragilis infection but are unavailable in the United States.